Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eurico Pereira has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions

    by Eurico Pereira, Filipa Pereira, Gabriela Campos, Ana M. Abrantes, Maria F. Botelho, Pedro Silva-Vaz, Ana S. Pires

    Purpose of Review: Radiotherapy remains a fundamental pillar of cancer treatment, however its efficacy is still often limited by tumor radioresistance and toxicity to surrounding healthy tissues. Poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged as potent radiosensitizers by impairing DNA repair mechanisms, particularly base excision repair, thereby enhancing the cytotoxic effects of ionizing radiation (IR). This review provides a critical narrative synthesis, based on a structured literature search, consolidating current preclinical and clinical evidence on the therapeutic potential of combining PARPi with various IR modalities, including X-rays, γ-rays, α- and β-particles, protons, and carbon ions, across a broad spectrum of tumor types. Recent Findings: The findings reveal that PARPi consistently enhance radiosensitivity, with the magnitude of effect influenced by radiation type, tumor-specific DNA repair capacity, and PARPi pharmacodynamics. Notably, combinations with high-LET radiation ( e.g. , carbon ions) demonstrate superior efficacy in certain contexts, while emerging data highlights the immunomodulatory potential of PARPi plus IR strategies via cGAS-STING pathway activation. Clinical trials confirm the feasibility of these combinations, although toxicity profiles vary by tumor type and treatment regimen. Summary: This review underscores the promise of PARPi plus radiotherapy combinations and identifies key avenues for future research, including biomarker-driven patient stratification and the development of triple-combination strategies to optimize therapeutic outcomes.

  • Open Access

    Influence of the pH Synthesis of Fe3O4 Magnetic Nanoparticles on Their Applicability for Magnetic Hyperthermia: An In Vitro Analysis

    by Bárbara Costa, Eurico Pereira, Vital C. Ferreira-Filho, Ana Salomé Pires, Laura C. J. Pereira, Paula I. P. Soares, Maria Filomena Botelho, Fernando Mendes, Manuel P. F. Graça, Sílvia Soreto Teixeira

    Nanotechnology, specifically magnetic nanoparticles (MNPs), is revolutionizing cancer treatment. Magnetic hyperthermia is a treatment that, using MNPs, can selectively kill cancer cells without causing damage to the surrounding tissues. Background/Objectives: This work aimed to analyze how the synthesis conditions, namely, how the pH of the reaction can influence the magnetic properties of Fe3O4 nanoparticles for magnetic hyperthermia, using the hydrothermal synthesis. Methods: For the hydrothermal synthesis, FeCl3·6H2O and FeCl2·4H2O were mixed with different quantities of NaOH to adjust the pH. After obtaining a black precipitate, the samples were placed in an autoclave at 200 °C for 60 h, followed by a washing and drying phase. The obtained MNPs were analyzed using X-Ray Diffraction (XRD), Transmission Electron Microscopy, a Superconducting Quantum Interference Device, Specific Absorption Rate analysis, and cytotoxicity assays. Results: Different MNPs were analyzed (9.06 < pH < 12.75). The XRD results showed the presence of various iron oxide phases (magnetite, maghemite, and hematite), resulting from the oxidization of the iron phases present in the autoclave. In terms of the average particle size, it was verified that, by increasing the pH value, the size decreases (from 53.53 nm to 9.49 nm). Additionally, MNPs possess a superparamagnetic behaviour with high SAR values (above 69.3 W/g). Conclusions: It was found that the pH of the reaction can influence the size, morphology, magnetization, and thermal efficiency of the MNP. The MNP with the highest composition of Fe3O4 was synthesized with a pH of 12.75, with a cubic morphology and a SAR value of 92.7 ± 3.2 W/g.


  • Differentiation Stage Predicts Radiosensitivity in Mesenchymal-Like Pancreatic Cancer

    by Tingshi Su, Xinjian Yu, Mojtaba Hoseini-Ghahfarokhi, David B. Flint, Scott J. Bright, Joana I.D.S. Antunes, David K.J. Martinus, Mandira Manandhar, Mariam Ben Kacem, Poliana C. Marinello, et al.


  • Open Access

    Targeting Hydroxybenzoic Acids to Mitochondria as a Strategy to Delay Skin Ageing: An In Vitro Approach

    by Carlos Fernandes, Fernando Cagide, Jorge Simões, Carlos Pita, Eurico Pereira, Afonso J. C. Videira, Pedro Soares, José F. S. Duarte, António M. S. Santos, Paulo J. Oliveira, et al.

    Targeting antioxidants to mitochondria is considered a promising strategy to prevent cellular senescence and skin ageing. In this study, we investigate whether four hydroxybenzoic acid-based mitochondria-targeted antioxidants (MitoBENs, MB1-4) could be used as potential active ingredients to prevent senescence in skin cells. Firstly, we evaluated the chemical stability, cytotoxicity, genotoxicity and mitochondrial toxicity of all compounds. We followed this by testing the antioxidant protective capacity of the two less toxic compounds on human skin fibroblasts. We then assessed the effects of the best hit on senescence, inflammation and mitochondrial remodeling on a 3D skin cell model, while also testing its mutagenic potential. Cytotoxicity and mitochondrial toxicity rankings were produced: MB3 < MB4 ≃ MB1 < MB2 and MB3 < MB1 < MB4 < MB2, respectively. These results suggest that pyrogallol-based compounds (MB2 and MB4) have lower cytotoxicity. The pyrogallol derivative, MB2, containing a 6-carbon spacer, showed a more potent antioxidant protective activity against hydrogen peroxide cytotoxicity. In a 3D skin cell model, MB2 also decreased transcripts related to senescence. In sum, MB2’s biological safety profile, good chemical stability and lack of mutagenicity, combined with its anti-senescence effect, converts MB2 into a good candidate for further development as an active ingredient for skin anti-ageing products.


  • Open Access

    Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies

    by Ricardo Teixo, Ana Salomé Pires, Eurico Pereira, Beatriz Serambeque, Inês Alexandra Marques, Mafalda Laranjo, Slavko Mojsilović, Roberto Gramignoli, Peter Ponsaerts, Andreina Schoeberlein, et al.

    The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.


  • Oxidative stress in bladder cancer: an ally or an enemy?

    by Fernando Mendes, Eurico Pereira, Diana Martins, Edgar Tavares-Silva, Ana Salomé Pires, Ana Margarida Abrantes, Arnaldo Figueiredo, Maria Filomena Botelho

    Bladder cancer (BC) is the most common cancer of the urinary tract and despite all innovations, remains a major challenge due to high morbidity and mortality. Genomic and epigenetic analyses allowed the discovery of new genes and pathways involved in the pathogenesis and regulation of BC. However, the effect on mortality has been modest and the development of new targets for BC treatment are needed. Recent evidence suggests that cancer cells are under increased stress associated with oncogenic transformation, with changes in metabolic activity and increased generation of reactive oxygen species (ROS). The increased amounts of ROS in cancer cells are associated with stimulation of cellular proliferation, promotion of mutations and genetic instability, as well as alterations in cellular sensitivity to anticancer agents. Since these mechanisms occur in cancer cells, there is a close link between oxidative stress (OS) and BC with implications in prevention, carcinogenesis, prognosis, and treatment. We address the role of OS as an enemy towards BC development, as well as an ally to fight against BC. This review promises to expand our treatment options for BC with OS-based therapies and launches this approach as an opportunity to improve our ability to select patients most likely to respond to personalized therapy.


  • Open Access

    Cold Atmospheric Plasma, a Novel Approach against Bladder Cancer, with Higher Sensitivity for the High-Grade Cell Line

    by Edgar Tavares-Da-Silva, Eurico Pereira, Ana S. Pires, Ana R. Neves, Catarina Braz-Guilherme, Inês A. Marques, Ana M. Abrantes, Ana C. Gonçalves, Francisco Caramelo, Rafael Silva-Teixeira, et al.

    Antitumor therapies based on Cold Atmospheric Plasma (CAP) are an emerging medical field. In this work, we evaluated CAP effects on bladder cancer. Two bladder cancer cell lines were used, HT-1376 (stage III) and TCCSUP (stage IV). Cell proliferation assays were performed evaluating metabolic activity (MTT assay) and protein content (SRB assay). Cell viability, cell cycle, and mitochondrial membrane potential (Δψm) were assessed using flow cytometry. Reactive oxygen and nitrogen species (RONS) and reduced glutathione (GSH) were evaluated by fluorescence. The assays were carried out with different CAP exposure times. For both cell lines, we obtained a significant reduction in metabolic activity and protein content. There was a decrease in cell viability, as well as a cell cycle arrest in S phase. The Δψm was significantly reduced. There was an increase in superoxide and nitric oxide and a decrease in peroxide contents, while GSH content did not change. These results were dependent on the exposure time, with small differences for both cell lines, but overall, they were more pronounced in the TCCSUP cell line. CAP showed to have a promising antitumor effect on bladder cancer, with higher sensitivity for the high-grade cell line.


  • Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Exportin 1 (Xpo1) Antagonist Selinexor (Kpt-330) in Patients (Pts) with Platinum Resistant/Refractory Ovarian Cancer (Ovca)

    by J. Martignetti, A.R.A. Razak, Y. Chen, N.Y. Gabrail, J.F. Gericitano, C. Camacho, E. Pereira, B. Evans, P. Dottino, D. McCauley, et al.

    Aim: Increased XPO1 expression has been linked to progression of OvCa. Nearly all tumor suppressor proteins (TSPs) are transported out of the nucleus exclusively by XPO1 and thereby inactivated. The XPO1 inhibitor, Selinexor, forces the nuclear retention and activation of >10 TSPs resulting in OvCa cell death. Methods: SINE induced TSP nuclear localization and induction of apoptosis were tested in OvCa cell lines and patient-derived cells. Combination with cisplatin was assessed in vitro & in patient-derived xenograft models (30 mg/m2 po, 3 times/week). An on-going Phase 1 (KCP-330-002, NCT01607905) in pts with solid tumors, oral selinexor (8 -10 doses/4-week cycle) was administered to pts with heavily pretreated OvCa that were progressing on study entry. Response was evaluated every 2 cycles (RECIST 1.1). Results: SINE potently induced cell death in platinum-sensitive and -resistant OvCa cell lines (IC50s < 0.12 µM). Nuclear accumulation and activation of p53 & other TSP was shown. In all 25 patient-derived cell lines tested, SINE induced potent cytotoxicity and showed marked synergy with cisplatin. Synergy was also observed in an in vivo murine model, resulting in increased overall survival. Seven pts with OvCa resistant/refractory to platinums and other agents (median age 55 yrs; ECOG PS 0/1: 3/4; median prior therapies: 5) were treated with 30-35 mg/m2 oral selinexor. No grade 4 AEs were reported. The most common AEs (Grade 1/2/3) were fatigue (14%/71%/0%), nausea (57%/43%/0%), diarrhea (71%/0%/0%), & vomiting (29%/43%/0%); manageable with supportive care. PK analysis showed Cmax of 0.5-1 µM & AUC0-inf 2800-4000 ng*h/mL, which exceed levels in vitro and in animal models. RECIST response was evaluable in 5 pts: 1 PR (5 months), 2 SD (4 & 10+ months) and 2 PD. Conclusions: Selinexor treatment provides synergistic activity with cisplatin in preclinical models. In pts, selinexor shows preliminary single agent antitumor activity against heavily pretreated platinum resistant/refractory OvCa. A single agent phase 2 study is ongoing (NCT02025985) & combination studies are planned. Disclosure: All authors have declared no conflicts of interest.